Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Oct 15, 2026; 18(10): 118805
Published online Oct 15, 2026. doi: 10.4251/wjgo.118805
Published online Oct 15, 2026. doi: 10.4251/wjgo.118805
Performance status as the central guide in managing primary gastrointestinal lymphoma
Wen-Juan Qiu, Yan Chen, School of Basic Medicine Science, Putian University, Putian 351100, Fujian Province, China
Wen-Juan Qiu, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, China
Li Chen, Cardiovascular Surgery Intensive Care Unit, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350000, Fujian Province, China
Cheng-Fei Zhao, School of Pharmacy and Medical Technology, Putian University, Putian 351100, Fujian Province, China
Cheng-Fei Zhao, Key Laboratory of Pharmaceutical Analysis and Laboratory Medicine in University of Fujian Province, Putian University, Putian 351100, Fujian Province, China
Co-first authors: Wen-Juan Qiu and Yan Chen.
Author contributions: Zhao CF and Qiu WJ mainly designed this paper; Zhao CF, Qiu WJ, Chen Y and Chen L checked and proofread this paper; Qiu WJ, Chen Y, Chen L and Zhao CF searched related literatures and information for this paper. All authors have read and approve the final manuscript. Qiu WJ and Chen Y contributed equally to this work as co-first authors.
Supported by Scientific Research Project of Putian University, No. 2022059; Special Project for Outstanding Young Talents of Putian University, No. 2024072; and Natural Science Foundation of Fujian Province, No. 2023J01160.
Conflict-of-interest statement: The authors declare that there is no conflict of interest in this paper.
Corresponding author: Cheng-Fei Zhao, MD, PhD, Associate Professor, School of Pharmacy and Medical Technology, Putian University, No. 1133 Xueyuan Road, Chengxiang District, Putian 351100, Fujian Province, China. zhaochengfei209@163.com
Received: January 12, 2026
Revised: February 15, 2026
Accepted: March 2, 2026
Published online: October 15, 2026
Processing time: 247 Days and 19.1 Hours
Revised: February 15, 2026
Accepted: March 2, 2026
Published online: October 15, 2026
Processing time: 247 Days and 19.1 Hours
Core Tip
Core Tip: This study discusses primary gastrointestinal lymphoma (PGIL), a rare and heterogeneous cancer. It highlights a key finding from a recent study: Poor performance status (Eastern Cooperative Oncology Group score ≥ 2) is the strongest independent predictor of survival. We argue for the renewed integration of this fundamental clinical assessment with modern molecular profiling to guide personalized, risk-adapted therapy for PGIL, ensuring treatment intensity matches the patient’s physiologic capacity.